PHP30 CAN PRICING SCHEMES IMPROVE MARKET ACCESS FOR INNOVATIVE HIGH PRICED DRUGS?
نویسندگان
چکیده
منابع مشابه
Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
Key Points - Representatives of the pharmaceutical industry call for a broader recognition of value within the assessment and appraisal of innovative drugs- Focus on value within the assessment and appraisal of drugs is jeopardized by financial drives as the side of industry and at the side of the payers- A well-considered value-framework, with attention for patient reported outcomes, societal ...
متن کاملPricing in the Market for Anticancer Drugs.
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.
متن کاملAccess pricing and market structure
In telecommunications industries access charge problems are important issues during deregulation. In Japan and the US, deregulation also involves the issue of industrial structures as integration or divestiture of a long-distance sector. This paper analyzes access charge problems by introducing effects of the divestiture on cost functions. We show how the effects influence economic welfare unde...
متن کاملHigh-priced technology can be good value for money.
M edical technology is now subject to the same economic scrutiny that was historically reserved for public health and disease prevention programs. It has long been true that vaccination, health education, and screening programs have been required by both public and private health care agencies to prove their economic worth before they could be funded. A frequently encountered criterion for fund...
متن کاملMarket spiral pricing of cancer drugs.
Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. Twelve of the 13 new cancer drugs approved last year were priced above $100,000 annually (Table 1), and a 20% copayment makes them unaffordable, even for well-insured patients. What determines the escalating prices of cancer drugs? Pharmaceutical experts ofte...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2011
ISSN: 1098-3015
DOI: 10.1016/j.jval.2011.02.102